Research area
Cancer Immunotherapy
Immune-directed cancer treatments, including therapeutic vaccines and oncolytic approaches. Engineered cell products belong under Cell & Gene Therapy.
-
Evidence date ·How prostate tumors reshape the immune response
Review or Meta-AnalysisA 2021 review traces how immune signals, stromal cells and treatment can alter PD-L1 in prostate cancer, and why combinations remain experimental.
-
Evidence date ·When prostate cancer defenses meet immune-cell attack
Review or Meta-AnalysisA 2021 review of prostate cancer cell and mouse studies shows why immune treatment may need other approaches—and where patient benefit remains unproven.
-
Evidence date ·How engineered immune cells might be designed and delivered for glioblastoma
Review or Meta-AnalysisA 2021 review explains how engineered T and natural killer cells face changing tumour targets, difficult delivery and uncertain durability in glioblastoma.
-
Evidence date ·How persistent senescent cells reshape the tumor neighborhood
Review or Meta-AnalysisAn October 2025 review examines how senescent cells alter tumor immunity, what aging clocks measure, and preclinical tests of selective drug delivery.
-
Evidence date ·Why cancer researchers might remove cells that have stopped dividing—or induce that state
Review or Meta-AnalysisA map of 2,396 studies compares ways to remove, quiet, or induce senescent cells—and shows why research patterns are not patient benefit.
-
Evidence date ·How aging immune cells and tumor surroundings shape treatment in older adults
Review or Meta-AnalysisTracked over timeA 2026 review examines cancer immunotherapy outcomes in older adults and preclinical ways to clear senescent cells or induce senescence in tumors.
-
Evidence date ·Should cancer treatment remove impaired T cells or restore them?
Review or Meta-AnalysisTracked over timeA review explains why aged T cells may lose the ability to multiply yet retain tumor-killing activity, and how restoration differs from removal.
-
Evidence date ·When aging changes the immune neighborhood around a tumor
Review or Meta-AnalysisTracked over timeA 2021 review reports mixed findings on age and cancer immunotherapy. Removing senescent cells to improve treatment was still an unproven proposal.
-
Evidence date ·How tumors leave immune cells less able to fight and multiply
Review or Meta-AnalysisA review examines why restoring exhausted T cells may not be enough to sustain attacks on cancer, and why targeting senescent cells still needs clinical testing.